Activation of Collimators Irradiated With Clinical Proton Beams and Development of a Semiempirical Model for Activity Calculation

Patient-specific collimators used in proton therapy are activated after use. The aim of this work is to assess the residual activity in brass collimators considering clinical beams, so far studied only for monoenergetic beams, and to develop a model to calculate the activity. Eight brass collimators irradiated with different clinical and monoenergetic beams were included in the study. The collimators were analyzed with gamma spectrometry in the framework of three independent studies carried out at the two French proton therapy sites. Using FLUKA (a fully integrated particle physics Monte Carlo simulation package), simulations were performed to determine radionuclides and activities for all the collimators. The semiempirical model was built using data calculated with FLUKA for a range of clinical beams (different maximum proton energies, modulations, and doses). It was found that there was global coherence in experimental results from different studies. The relevant radionuclides at 1 mo postirradiation were 57Co, 58Co, and 65Zn, and additionally, 54Mn, 56Co, and 60Co for high-energy beams. For nondegraded monoenergetic beams, differences between FLUKA and spectrometry were within those reported in reference benchmark studies (±30%). Due to the use of perfect monochromatic sources in the FLUKA model, FLUKA results systematically underestimated experimental activities for clinical beams, especially for 65Zn, depending on the beam energy spread (modulation, degradation, b...
Source: Health Physics - Category: Radiology Tags: PAPERS Source Type: research

Related Links:

PALO ALTO, Calif., Nov. 18, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the South Florida Proton Therapy Institute (SFPTI), a Proton International facility, on the campus of Delray Medical Center, has treated its first patient utilizing the Varian ProBeam® Compact single-room proton therapy system. Proton therapy can be used to treat many types of tumors including in the brain, head and neck, central nervous system and lung, and more precisely targets cancer cells...This story is related to the following:Radiotherapy Systems
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
CONCLUSIONS: This work demonstrate the clinical acceptability of substituting MR converted RSP images instead of CT for IMPT planning of prostate cancer. This further translates into higher contouring accuracy along with lesser imaging dose. PMID: 31734604 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Conclusion Here, we present a case of HMSC with early and progressive distant metastasis. We aim to add to an understanding of the behavior of this entity. Although this neoplasm may typically be indolent, further classification of high-risk features is necessary to identify rare aggressive cases. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: Journal of Neurological Surgery Reports - Category: Neurosurgery Authors: Tags: Case Report Source Type: research
The primary purpose of this study was to investigate the impact of an air gap (AG) on breast cancer plans that are generated using the intensity-modulated proton therapy technique.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Tags: Research Article Source Type: research
Proton therapy ’s direct and precise application of radiation for mid-stage lung cancer is being investigated in an ongoing phase III trial at the University of Cincinnati.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
CONCLUSION: In the presence of mediastinal involvement and absence of range shifters Raystation ADC may be clinically acceptable in lung IMPT. Otherwise, MC algorithm would be recommended to ensure accuracy of treatment plans. ADVANCES IN KNOWLEDGE: Although MC algorithm is more accurate compared to ADC in lung IMPT, ADC may be clinically acceptable where there is mediastinal involvement and absence of range shifters. PMID: 31696729 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma. It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years. “This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.” The noninvasive Tumor Treating...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract Proton radiation therapy has been used clinically since 1952, and major advancements in the last 10 years have helped establish protons as a major clinical modality in the cancer-fighting arsenal. Technologies will always evolve, but enough major breakthroughs have been accomplished over the past 10 years to allow for a major revolution in proton therapy. This paper summarizes the major technology advancements with respect to beam delivery that are now ready for mass implementation in the proton therapy space and encourages vendors to bring these to market to benefit the cancer population worldwide. We st...
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
We described GEP induced by both treatments, highlighting for the first time, the cell pathways induced by Si306. Summarizing, our results suggesting this compound as a novel possible candidate to treat GBM in combination with PT.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
ConclusionsResults for 230 MeV protons show that with proposed BSA, proton beam current about 5.75 μA is required for this purpose.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
More News: France Health | Physics | Proton Therapy | Radiology | Study